Charles Schwab Investment Management Inc. Lowers Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Charles Schwab Investment Management Inc. cut its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 1.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 298,949 shares of the company’s stock after selling 3,321 shares during the period. Charles Schwab Investment Management Inc. owned about 0.44% of Amylyx Pharmaceuticals worth $1,130,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of AMLX. Walleye Capital LLC boosted its holdings in Amylyx Pharmaceuticals by 986.5% during the third quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock worth $2,173,000 after purchasing an additional 608,874 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Amylyx Pharmaceuticals by 17.5% in the 3rd quarter. Geode Capital Management LLC now owns 551,039 shares of the company’s stock worth $1,786,000 after buying an additional 82,173 shares during the last quarter. FMR LLC grew its holdings in shares of Amylyx Pharmaceuticals by 292.0% in the third quarter. FMR LLC now owns 221,001 shares of the company’s stock valued at $716,000 after acquiring an additional 164,622 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Amylyx Pharmaceuticals by 144.4% in the third quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock valued at $455,000 after acquiring an additional 83,048 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Amylyx Pharmaceuticals by 91.1% during the third quarter. Barclays PLC now owns 84,572 shares of the company’s stock valued at $274,000 after acquiring an additional 40,319 shares during the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Amylyx Pharmaceuticals Trading Down 5.4 %

Shares of NASDAQ AMLX opened at $3.66 on Monday. The stock has a fifty day simple moving average of $3.55 and a two-hundred day simple moving average of $4.04. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $7.27. The firm has a market cap of $324.28 million, a price-to-earnings ratio of -0.96 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million during the quarter. Analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, Director Bernhardt G. Zeiher bought 10,000 shares of the stock in a transaction on Thursday, March 20th. The shares were acquired at an average price of $3.70 per share, with a total value of $37,000.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $37,000. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Justin B. Klee sold 7,471 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $4.04, for a total value of $30,182.84. Following the completion of the transaction, the chief executive officer now directly owns 3,176,788 shares of the company’s stock, valued at $12,834,223.52. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,169 shares of company stock worth $97,274 over the last quarter. Corporate insiders own 11.70% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.